17730-18-6

Basic information

• Product Name: Z-PRO-MET-OH
• Synonyms: N-CARBOBENZOXY-L-PROPYL-L-METHIONINE;Z-L-PROLYL-L-METHIONINE;Z-PRO-MET-OH;N-[1-[(phenylmethoxy)carbonyl]-L-prolyl]-L-methionine;Z-L-Pro-L-Met-OH;Einecs 241-723-3
• CAS NO: 17730-18-6
• Molecular Formula: C₁₈H₂₄N₂O₅S
• Molecular Weight: 380.46
• EINECS: 241-723-3
• Mol File: 17730-18-6.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 649.4 °C at 760 mmHg
• Flash Point: 346.6 °C
• Appearance: /
• Density: 1.297 g/cm³
• Vapor Pressure: 9.41E-18mmHg at 25°C
• Refractive Index: 1.585
• Storage Temp.: -15°C
• CAS DataBase Reference: Z-PRO-MET-OH(CAS DataBase Reference)
• NIST Chemistry Reference: Z-PRO-MET-OH(17730-18-6)
• EPA Substance Registry System: Z-PRO-MET-OH(17730-18-6)

Safety Data

• Hazardous Substances Data: 17730-18-6(Hazardous Substances Data)

Usage

General Description

Z-PRO-MET-OH is a chemical compound with the molecular formula C9H17NO3. It is a derivative of L-proline and is commonly used as a reagent in organic synthesis. Z-PRO-MET-OH is a white solid that is soluble in water and has a melting point of 119-121°C. It is often used as a building block in the preparation of peptide and peptidomimetic compounds, and as a protecting group for amino acids in peptide synthesis. It has also been studied for its potential pharmaceutical applications, including as an anti-inflammatory and anti-cancer agent. Overall, Z-PRO-MET-OH is an important chemical in the field of organic chemistry and pharmaceutical research.

InChI:InChI=1/C18H24N2O5S/c1-26-11-9-14(17(22)23)19-16(21)15-8-5-10-20(15)18(24)25-12-13-6-3-2-4-7-13/h2-4,6-7,14-15H,5,8-12H2,1H3,(H,19,21)(H,22,23)

Upstream product

• 886981-23-3 benzyl (2S)-2-(1H-1,2,3-benzotriazol-1-ylcarbonyl)tetrahydro-1H-pyrrole-1-carboxylate 
• 63-68-3 L-methionine 
• 1148-11-4 N-Benzyloxycarbonyl-L-proline 
• 17445-57-7 Z-Pro-Met-OMe 

Downstream Products

• 110529-59-4 N-(benzyloxycarbonyl)-L-prolyl-L-methionine succinimido ester 
• 110512-43-1 methyl N--8-amino-2,6-anhydro-3,8-dideoxy-D-glycero-D-talo-octonate 

Relevant articles and documents

Novel Macrocyclic Peptidomimetics Targeting the Polo-Box Domain of Polo-Like Kinase 1

The polo-box domain (PBD) of Plk1 is a promising target for cancer therapeutics. We designed and synthesized novel phosphorylated macrocyclic peptidomimetics targeting PBD based on acyclic phosphopeptide PMQSpTPL. The inhibitory activities of 16e on Plk1-PBD is >30-fold higher than those of PMQSpTPL. Both 16a and 16e possess excellent selectivity for Plk1-PBD over Plk2/3-PBD. Analysis of the cocrystal structure of Plk1-PBD in complex with 16a reveals that the 3-(trifluoromethyl)benzoyl group in 16a interacts with Arg516 through a π-stacking interaction. This π-stacking interaction, which has not been reported previously, provides insight into the design of novel and potent Plk1-PBD inhibitors. Furthermore, 16h, a PEGlyated macrocyclic phosphopeptide derivative, induces Plk1 delocalization and mitotic failure in HeLa cells. Also, the number of phospho-H3-positive cells in a zebrafish embryo increases in proportion to the amount of 16a. Collectively, the novel macrocyclic peptidomimetics should serve as valuable templates for the design of potent and novel Plk1-PBD inhibitors.